Expedition Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
San Francisco, California, United StatesPhone Number
(917) 291-5744Website
www.expeditiontx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Expedition Therapeutics
Expedition Therapeutics is a biotechnology company focused on developing disease-controlling treatments for chronic obstructive pulmonary disease by targeting fundamental disease mechanisms. Its approach centers on neutrophilic inflammation, a clinically validated pathway associated with tissue damage, airway remodeling, and progressive lung function decline. The company is advancing an oral, once-daily DPP1 inhibitor designed to address this underlying inflammatory pathway and provide meaningful, sustained benefits for patients with COPD.Explore more
Expedition Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Expedition Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Expedition Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Expedition Therapeutics
Funding: Get notified immidiatlly once Expedition Therapeutics has new funding data
Click to see if Expedition Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on Expedition Therapeutics recently announced quarterly report
Product Launch: Get notified when Expedition Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Check out if Expedition Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Expedition Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Expedition Therapeutics as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Expedition Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Expedition Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Expedition Therapeutics.
Expedition Therapeutics financials insights
Gather financial insights about Expedition Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Series A
$165M
2026
Series B
$115M
Expedition Therapeutics Tech Stack
A closer look at the technologies used by Expedition Therapeutics
See more technologies
Most Recent Scoops
Funding
Funding
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
Funding
Funding
Expedition Therapeutics News & Media
Expedition Therapeutics Closes $115 Million Series B
SAN FRANCISCO, CA, Expedition Therapeutics, a clinical-stage biotechnology company developing novel oral small molecule therapies for inflammatory and respiratory diseases, announced the closing of an oversubscribed $115 million Series B financing.Expedition Therapeutics Lands $115M Series B
SAN FRANCISCO, CA, Expedition Therapeutics has announced the closing of an oversubscribed $115 million Series B financing round.NYSE Content Update: Expedition Therapeutics Secures $115 Million Series B
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Aug. 5, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before...Expedition raises $115m Series B to advance COPD drug - BioXconomy
Expedition secures funding to move EXPD-101 through Phase II trials, targeting neutrophilic inflammation in COPD patients
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Expedition Therapeutics
Sign Up For FreeTo access detailed company insights
Expedition Therapeutics is a biotechnology company focused on developing disease-controlling treatments for chronic obstructive pulmonary disease by targeting fundamental disease mechanisms. Its approach centers on neutrophilic inflammation, a clinically validated pathway associated with tissue damage, airway remodeling, and progressive lung functi... Read More
